CTRI/2023/10/058310招募中1 期
A Prospective, Single-Dose, Single-Period Study to Evaluate the Pharmacokinetics and Tolerability of Trinbelimab (Recombinant Anti Rho-D Immunoglobulin) of Bharat Serums and Vaccines Ltd., India in Healthy, Adult, Rhesus-D Negative Non Sensitized Postmenopausal Female Subjects - NI
Bharat Serums and Vaccines Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Post-menopausal female subjects.
- •BMI between 18.5 and 29.9 kg/m2
- •Able to give voluntary written consent
排除标准
- •Rh-D positive post menopausal female and who are positive for anti-D IgG antibodies
- •Positive test for pregnancy
- •History or presence of clinically significant disease
- •Known hypersensitivity to antiD immunoglobulin
研究者
相似试验
已完成
1 期
A study in healthy male volunteers to look at how the test medicine ([Cyclohexane-U-14C]-MBS2320) is taken up, broken down and removed from the body when given by mouthPotential treatment of rheumatoid arthritis (RA) and idiopathic pulmonary fibrosis (IPF).Skin and Connective Tissue DiseasesISRCTN16794199Modern Biosciences Ltd6
已完成
1 期
A study in healthy male volunteers to look at how the radiolabeled test medicine ([14C]encaleret) is taken up, broken down and removed by the bodyAutosomal dominant hypocalcaemia type 1 (ADH1)Nutritional, Metabolic, EndocrineISRCTN59912845Calcilytix Therapeutics, Inc., a BridgeBio Company8
进行中（未招募）
1 期
A study in healthy male volunteers designed to investigate how the test medicine [14C]-CORT125329 is taken up, broken down and removed by the bodyISRCTN20653849Corcept Therapeutics (United States)6
已完成
不适用
AN OPEN-LABEL, SINGLE-DOSE, SINGLE-PERIOD STUDY DESIGNED TO ASSESS THE MASS BALANCE RECOVERY, METABOLITE PROFILE AND METABOLITE IDENTIFICATION OF [14C]-OLOROFIM ADMINISTERED VIA THE ORAL ROUTE TO HEALTHY MALE SUBJECTS.Serious fungal infections10017528NL-OMON48360F2G Biotech GmBH12
进行中（未招募）
1 期
A study to investigate the lung penetration of RO7223280 following intravenous administration in healthy participantsISRCTN16112706F. Hoffmann-La Roche Ltd40